<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446534</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1863</org_study_id>
    <nct_id>NCT03446534</nct_id>
  </id_info>
  <brief_title>The Norwegian Antibiotics for Pneumonia in Children Study</brief_title>
  <acronym>NAPiC</acronym>
  <official_title>The Norwegian Antibiotics for Pneumonia in Children Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinbeforsk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of amoxicillin in the treatment of lower airway infections in&#xD;
      preschool children. Half of the patients will receive amoxicillin, while the other half will&#xD;
      receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of the study is to determine if antibiotic therapy is beneficial in&#xD;
      children with pneumonia who do not have a highly suspicious bacterial infection, such as in&#xD;
      lobar pneumonia.&#xD;
&#xD;
      Secondary objective is to determine whether antibiotic use influence the microbial flora,&#xD;
      including antibiotic resistance, in the airways in the short or medium long term.&#xD;
&#xD;
      The study is a phase IV double-blind, placebo-controlled, multicenter, nationwide, randomized&#xD;
      superiority trial of amoxicillin versus placebo in children aged 1-5 years of age with a&#xD;
      lower respiratory infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a phase IV double-blind, placebo-controlled, multicenter, nationwide, randomized superiority trial of amoxicillin versus placebo in children aged 1-5 years of age with a lower respiratory infection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapy Failure</measure>
    <time_frame>Within 7 days after inclusion</time_frame>
    <description>Therapy failure as defined by attending physician, leading to end of intervention and administration of open-label antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thereapy failure leading to intravenous antibiotic therapy</measure>
    <time_frame>Within 7 days after inclusion</time_frame>
    <description>Therapy failure as defined by attending physician, leading to intravenous antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever</measure>
    <time_frame>Up to 21 days after inclusion</time_frame>
    <description>Duration of fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms of pneumonia</measure>
    <time_frame>Up to 21 days after inclusion</time_frame>
    <description>Duration of cough or respiratory distress (tachypnoe, retractions, grunting respiration or nasal flaring.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">884</enrollment>
  <condition>Pneumonia Childhood</condition>
  <condition>Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo mixture 0.25ml/kg every 8 hours for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Imacillin mixture</description>
    <arm_group_label>Amoxicillin</arm_group_label>
    <other_name>Imacillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo manufactured to mimic amoxicillin mixture (Imacillin)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 12-59 months&#xD;
&#xD;
          2. Fever:&#xD;
&#xD;
             a. Temperature ≥ 38.0 at inclusion or reported within the last 24 hours&#xD;
&#xD;
          3. Tachypnoe, age specific 12-17mnd ≥ 46 breaths per minute 18-23mnd ≥ 40 breaths per&#xD;
             minute 24-35mnd ≥ 34 breaths per minute 36-47mnd ≥ 29 breaths per minute 48-59mnd ≥ 27&#xD;
             breaths per minute&#xD;
&#xD;
          4. ≥ 1 sign of lower airway inflammation&#xD;
&#xD;
               1. Cough (at inclusion or reported within the last 6 hours)&#xD;
&#xD;
               2. Chest retractions (jugular, intercoastally or subcoastally)&#xD;
&#xD;
               3. Grunting respiration&#xD;
&#xD;
               4. Nasal flaring&#xD;
&#xD;
               5. Crepitations by pulmonary auscultation&#xD;
&#xD;
               6. Hypoxia (SpO2 ≤ 90%)&#xD;
&#xD;
          5. Weight between 6.0 and 28.0 kg. • Signed informed consent and expected cooperation of&#xD;
             the patients for the treatment and follow up must be obtained and documented according&#xD;
             to ICH GCP, and national/local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical suspicion of bacterial pneumonia based upon a temperature ≥39.0°C and at&#xD;
             least one of the following:&#xD;
&#xD;
               1. Bronchial breathing sounds&#xD;
&#xD;
               2. Unilaterally decreased breath sounds or unilateral percussion dullness&#xD;
&#xD;
               3. Pulmonary lobar consolidation and/or radiological high suspicion of empyema on&#xD;
                  chest x-ray if this is obtained prior to inclusion in the trial.&#xD;
&#xD;
          2. Evidence of any bacterial infection requiring systemic antibiotics, including, but not&#xD;
             exclusively:&#xD;
&#xD;
               1. Clinical septicaemia&#xD;
&#xD;
               2. Urinary tract infection&#xD;
&#xD;
               3. Meningitis&#xD;
&#xD;
          3. Systemic antibiotics received within the last 7 days&#xD;
&#xD;
          4. Pulmonary lobar consolidation and/or radiological high suspicion of empyema on chest&#xD;
             x-ray if this is obtained prior to inclusion in the trial.&#xD;
&#xD;
          5. History of any serious underlying disease that can increase the risk of bacterial&#xD;
             pulmonary infections, including but not limited to:&#xD;
&#xD;
               1. Haematological or oncological&#xD;
&#xD;
               2. Immunodeficiency&#xD;
&#xD;
               3. Congenital heart disease&#xD;
&#xD;
               4. Neuromuscular impairment&#xD;
&#xD;
               5. Development disorder, including Downs syndrome&#xD;
&#xD;
               6. Bronchopulmonary dysplasia, cystic fibrosis, primary ciliary dyskinesia, poorly&#xD;
                  controlled asthma or other severe chronic lung diseases&#xD;
&#xD;
          6. Signs of lower obstructive airways with both of the following present by auscultation:&#xD;
&#xD;
               1. prolonged expiration and&#xD;
&#xD;
               2. generalised expiratory wheeze&#xD;
&#xD;
          7. Stridor by auscultation.&#xD;
&#xD;
          8. History of known or suspected adverse reactions to amoxicillin, or any other&#xD;
             betalactam&#xD;
&#xD;
          9. Participating in another trial that might affect the current study&#xD;
&#xD;
         10. Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
             (e.g. not able to comply with study procedures)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Håvard O Skjerven</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Håvard O Skjerven, PhD</last_name>
    <phone>+47 41020249</phone>
    <email>h.o.skjerven@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Kristian Knudsen, MD</last_name>
    <phone>+4791631421</phone>
    <email>perkristiank@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Håvard Trønnes, PhD</last_name>
      <phone>95777862</phone>
      <email>havard.tronnes@ihelse.net</email>
    </contact>
    <investigator>
      <last_name>Håvard Trønnes, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset Bodø</name>
      <address>
        <city>Bodø</city>
        <zip>8005</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørg Evjenth</last_name>
      <phone>99258992</phone>
      <email>bjorg.evjenth@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bjørg Evjenth, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Trust</name>
      <address>
        <city>Grålum</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Olav Hunderi, MD</last_name>
      <phone>91880816</phone>
      <email>jon.olav.gjengsto.hunderi@so-hf.no</email>
    </contact>
    <investigator>
      <last_name>Jon Olav Hunderi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Inchley</last_name>
      <phone>90069276</phone>
      <email>christopher.inchley@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Christopher Inchley, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University of Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Håvard O Skjerven, PhD</last_name>
      <phone>41020249</phone>
      <email>h.o.skjerven@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <phone_ext>Skjerven</phone_ext>
      <email>h.o.skjerven@medisin.uio.no</email>
    </contact_backup>
    <investigator>
      <last_name>Håvard O Skjerven, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Kristian Knudsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Øymar, PhD</last_name>
      <phone>41633426</phone>
      <email>knut.oymar@sus.no</email>
    </contact>
    <investigator>
      <last_name>Knut Øymar, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Northern Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Klingenberg</last_name>
      <phone>91563167</phone>
      <email>claus.klingenberg@unn.no</email>
    </contact>
    <investigator>
      <last_name>Claus Klingenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Döllner, PhD</last_name>
      <phone>47667169</phone>
      <email>henrik.dollner@ntnu.no</email>
    </contact>
    <investigator>
      <last_name>Henrik Döllner, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital Trust</name>
      <address>
        <city>Ålesund</city>
        <zip>6017</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torbjørn Nag</last_name>
      <phone>41638349</phone>
      <email>torbjorn.nag@helse-mr.no</email>
    </contact>
    <investigator>
      <last_name>Torbjørn Nag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 17, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Håvard Ove Skjerven</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>pre-school children</keyword>
  <keyword>antibiotics</keyword>
  <keyword>amoxicillin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

